Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BACKGROUND: Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications. We aimed to estimate the cost-effectiveness of sorafenib and TACE in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Chen, Shuling, Peng, Zhenwei, Wei, Mengchao, Liu, Weifeng, Dai, Zihao, Wang, Haibo, Mei, Jie, Cheong, Mingfong, Zhang, Hanmei, Kuang, Ming
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887167/
https://ncbi.nlm.nih.gov/pubmed/29621988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4308-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados